Why is a payday loan right for you Payday loan 50 up to
Payday loans uk

Race to the Hep C Cure

Posted on March 24, 2014 by in Hep Talk, LifeGuide

Race to the Cure Who are the biggest players now in eradicating hepatitis C? by Larry Buhl Beyond the implementation of the Affordable Care Act, one of the biggest healthcare stories of 2013 was the emerging race of pharmaceutical companies to bring new drugs to the market to cure hepatitis C. The advent of direct-acting [...]

Coffee & HCV

Posted on March 6, 2014 by in Hep Talk, LifeGuide

Coffee Talk Two studies shed light on HCV prevention & treatment by Larry Buhl A study on the long-term infectiousness of the hepatitis C virus (HCV) has implications for healthcare workers, IV drug users, and tattoo artists, while another study shows the benefits of coffee and tea on liver inflammation in chronic hepatitis C patients. [...]

HCV Serosorting

Posted on January 24, 2014 by in Hep Talk, LifeGuide

Testing, Testing Serosorting is common for IV drug users who know their HCV status by Larry Buhl A new study shows IV drug users who know they carry the hepatitis C virus are likely to consider their serostatus when deciding whether and with whom to share injection equipment. The results, published in the December 15, [...]

Direct-Acting Antivirals & HCV

Posted on December 31, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Two Agents New direct-acting antivirals cross a major hurdle                       The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) in October gave unanimous recommendations for approval of two next-generation direct-acting antivirals (DAAs) for hepatitis C, Janssen’s [...]

African Americans & HCV

Posted on December 4, 2013 by in Hep Talk, LifeGuide

“Race” Matters Researchers study disparities when it comes to African Americans & HCV by Larry Buhl               A growing number of clinicians and researchers want the African-American community to understand that not only is there a racial disparity in care and treatment, there are differences in the way HCV [...]

Hep C & Adult Films

Posted on October 30, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Hep X Does the porn industry have a hepatitis problem? Actors who work for legitimate adult entertainment producers, who are mostly based in Los Angeles, now have to submit to monthly tests for hepatitis B and C as well as for Trichomoniasis vaginalis, a sexually transmitted infection of the urogenital [...]

HCV Data Sharing

Posted on September 20, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Three Steps New hep C data sharing may lead to more testing Last year the U.S. Centers for Disease Control and Prevention (CDC) made a big stir in the medical community when it issued its recommendation that everyone in the Baby Boomer cohort be tested for hepatitis C, whether or [...]

ACA & HCV Care

Posted on August 30, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Location, Location, Location How will the Affordable Care Act affect HCV care? In October, open enrollment for state-based health insurance marketplaces as part of the Affordable Care Act, or ACA—or Obamacare, as it’s called by its detractors—will begin. Already the ACA has eliminated the discriminatory insurance practice of denying coverage [...]

Hep C & the War on Drugs

Posted on July 12, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl The War on Common Sense A new report advocates decriminalizing drug use to reduce Hep C The so-called “war on drugs” is creating an epidemic of hepatitis C. That’s the finding of a new report by the Global Commission on Drug Policy, which finds that drug war policies have caused [...]

Interferon-Free C

Posted on June 19, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Warp Speeds CROI researchers predict oral-only interferon-free treatment by 2014 Advances leading to new interferon-free treatments for hepatitis C were unveiled at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in March in Atlanta as researchers described results of next-generation direct-acting antiviral agents for both HCV monoinfected and HIV/HCV [...]